Safety Study to Evaluate FluMist in Immunocompromised Children

Bio2RDF uri

Safety Study to Evaluate FluMist in Immunocompromised Children

http://bio2rdf.org/clinicaltrials:NCT00112112

Bio2RDF identifier

NCT00112112

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00112112

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

The main purpose of thi ...... ray can be found in the nose.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety Study to Evaluate FluMist in Immunocompromised Children

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00112112 [clinicaltrials_resource:a82eea3f45d31b4453be1bca0a02ffb8]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:4d448e253df41a11608bdc678a766dee]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:65d42b67bfc29a16052fa097f4a5a4af]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:9a24212873c2afe1adbad24d43f7fed6]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:9fe095011f5f74be451bcf0b4ea28e74]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:0bf1746b7ec281fa37ac380bbfd56d61]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:1713aaa516449c861427468b96ca49a1]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:19cd1e72cf9053627051efb970d6f773]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:1e5788a4463bfec7d60bf9dce4a6f28e]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:1fafc0e1dd23902a9e6c3e2c31464530]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:2ad099eb193cfe12591fb118c16b94d7]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:2b0a840a2ce3c4bd49259936d82f79b7]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:32285bb580903762748d76742b52db80]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:38df0d1f9ccfe6b96011c465e77c672a]

Number of Participants Who Had Reactogenicity Events (REs) 0-42 days after study vaccination [clinicaltrials_resource:39d1fce678e212d007a1adbb742d5d10]

completion date [clinicaltrials_vocabulary:completion-date]

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Cancer [clinicaltrials_resource:7463543d784aa59ca86359a50ef58c8e]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

This study is a randomi ...... er administration of FluMist.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00112112 [clinicaltrials_resource:d88e4505a7df32872da44f8fba465fd9]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2012-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

FluMist [clinicaltrials_resource:1b40be519ddbb844e81b89defe030835]

Placebo [clinicaltrials_resource:54fc08458e91dcd0af60668da7e1f313]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

cancer, pediatric, influenza, vaccine

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

MedImmune LLC [clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30]

link [clinicaltrials_vocabulary:link]

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product [clinicaltrials_resource:084396fac4ae068b8942452cdbd754c6]

Click here and search for drug information provided by the FDA [clinicaltrials_resource:7a06845f49ed0040937032af97edab4d]

location [clinicaltrials_vocabulary:location]

University of Rochester School of Medicine & Dentistry [clinicaltrials_resource:72623e4ea41ca166aafd579c5f6bcbcd]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00112112

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase I Randomized, Double-B ...... Ages 5 Through 17 Years of Age

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

MI-CP114

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Number of Participants Who Had Reactogenicity Events (REs) [clinicaltrials_resource:NCT00112112/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Raburn Mallory, MD [clinicaltrials_resource:f308fc337a6db55943e94e6f76b6be2e]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00112112 [clinicaltrials_resource:0a3fc7887b269ad67447c884903135f7]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00112112 [clinicaltrials_resource:c1c5f84ba64e2ac90b711f23c3533bd0]

responsible party [clinicaltrials_vocabulary:responsible-party]

Raburn Mallory, Senior Director, Clinical Development, MedImmune, LLC [clinicaltrials_resource:bb471b55829e22ccf87b4dd3fd8f3fab]

source [clinicaltrials_vocabulary:source]

MedImmune LLC [clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30]

start date [clinicaltrials_vocabulary:start-date]

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00112112 study design [clinicaltrials_resource:b18a69b8dcca6ed6ae9d2746a61d3ac4]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00112112

verification date [clinicaltrials_vocabulary:verification-date]

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00112112

http://www.w3.org/2001/XMLSchema#string